NCT04329728 - The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

April 1, 2026

Study Completion Date

December 1, 2026

Conditions

Lymphoid Malignancies

Interventions

DRUG

AVM0703

Intravenous infusion over \~1 hours

Trial Locations (11)

34613

RECRUITING

ASCLEPES Research Centers, Weeki Wachee

38120

RECRUITING

Baptist Clinical Research Institute, Memphis

40207

RECRUITING

Norton Cancer Institute, Louisville

44718

RECRUITING

Gabrail Cancer Center Research,, Canton

60612

RECRUITING

University of Illinois at Chicago Cancer Center, Chicago

68124

RECRUITING

Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha

75235

RECRUITING

University of Texas(UT) Southwestern-Children's Medical Center, Dallas

90017

RECRUITING

Los Angeles Cancer Network, Los Angeles

90095

RECRUITING

UCLA Medical Center of Hematology/Oncology, Los Angeles

91010

RECRUITING

City of Hope, Duarte

92705

RECRUITING

Innovative Clinical Research Institute, Whittier